These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 11665975

  • 1. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A, Magder LS, Barr SG, Petri M.
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [Abstract] [Full Text] [Related]

  • 2. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A, Barr SG, Magder LS, Petri M.
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [Abstract] [Full Text] [Related]

  • 3. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 4. A surge in anti-dsDNA titer predicts a severe lupus flare within six months.
    Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA.
    Lupus; 2014 Mar; 23(3):293-8. PubMed ID: 24316605
    [Abstract] [Full Text] [Related]

  • 5. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus.
    van den Berg L, Nossent H, Rekvig O.
    Clin Rheumatol; 2006 May; 25(3):347-52. PubMed ID: 16328091
    [Abstract] [Full Text] [Related]

  • 6. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
    Ng KP, Manson JJ, Rahman A, Isenberg DA.
    Arthritis Rheum; 2006 Dec 15; 55(6):900-4. PubMed ID: 17139667
    [Abstract] [Full Text] [Related]

  • 7. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C, Medina-Rosas J, Santos AM, Jaimes DA, Arbeláez AM, Romero C, Cortes A, Londono J.
    J Rheumatol; 2016 Sep 15; 43(9):1657-64. PubMed ID: 27134246
    [Abstract] [Full Text] [Related]

  • 8. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
    Závada J, Uher M, Svobodová R, Olejárová M, Hušáková M, Ciferská H, Hulejová H, Tomčík M, Šenolt L, Vencovský J.
    Arthritis Res Ther; 2015 Nov 25; 17():341. PubMed ID: 26608564
    [Abstract] [Full Text] [Related]

  • 9. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus.
    Mok CC, Ho LY, Leung HW, Wong LG.
    Transl Res; 2010 Dec 25; 156(6):320-5. PubMed ID: 21078493
    [Abstract] [Full Text] [Related]

  • 10. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
    Thanou A, Chakravarty E, James JA, Merrill JT.
    Rheumatology (Oxford); 2014 Dec 25; 53(12):2175-81. PubMed ID: 24729400
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
    Ward MM, Marx AS, Barry NN.
    J Rheumatol; 2000 Mar 25; 27(3):664-70. PubMed ID: 10743805
    [Abstract] [Full Text] [Related]

  • 12. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB.
    Arthritis Rheum; 2006 Nov 25; 54(11):3623-32. PubMed ID: 17075807
    [Abstract] [Full Text] [Related]

  • 13. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
    Yee CS, Farewell V, Isenberg DA, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, D'Cruz D, Khamashta MA, Maddison P, Gordon C.
    Arthritis Rheum; 2007 Dec 25; 56(12):4113-9. PubMed ID: 18050213
    [Abstract] [Full Text] [Related]

  • 14. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H, Li T, Chen S, Gu Y, Ye S.
    Arthritis Rheumatol; 2015 Dec 25; 67(12):3190-200. PubMed ID: 26245802
    [Abstract] [Full Text] [Related]

  • 15. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus.
    Brunner HI, Mina R, Pilkington C, Beresford MW, Reiff A, Levy DM, Tucker LB, Eberhard BA, Ravelli A, Schanberg LE, Saad-Magalhaes C, Higgins GC, Onel K, Singer NG, von Scheven E, Itert L, Klein-Gitelman MS, Punaro M, Ying J, Giannini EH.
    Arthritis Care Res (Hoboken); 2011 Sep 25; 63(9):1213-23. PubMed ID: 21618452
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug 25; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

  • 17. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.
    Nasiri S, Karimifar M, Bonakdar ZS, Salesi M.
    Rheumatol Int; 2010 Nov 25; 30(12):1605-9. PubMed ID: 19809816
    [Abstract] [Full Text] [Related]

  • 18. Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review.
    Floris A, Piga M, Cauli A, Mathieu A.
    Autoimmun Rev; 2016 Jul 25; 15(7):656-63. PubMed ID: 26921641
    [Abstract] [Full Text] [Related]

  • 19. Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus.
    Sjoholm AG, Martensson U, Sturfelt G.
    J Rheumatol; 1997 May 25; 24(5):871-8. PubMed ID: 9150075
    [Abstract] [Full Text] [Related]

  • 20. Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies.
    Narayanan K, Marwaha V, Shanmuganandan K, Shankar S.
    Med J Armed Forces India; 2010 Apr 25; 66(2):102-7. PubMed ID: 27365721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.